» Articles » PMID: 36275824

Renal Involvement As a Unique Manifestation of Hemophagocytic Syndrome

Overview
Specialty General Medicine
Date 2022 Oct 24
PMID 36275824
Authors
Affiliations
Soon will be listed here.
Abstract

Renal-limited hemophagocytic syndrome (HPS) is a rare clinical setting characterized by abnormal activation of the immune system. Fever associated with pancytopenia, hepatosplenomegaly with liver dysfunction, and hypofibrinogenemia are usually observed in HPS. From a histological level, the presence of non-malignant macrophages infiltrating bone marrow and organs represents the hallmark of this condition. Non-malignant macrophages are associated with phagocytizing activities involving other blood cells. While primary HPS is usually associated with inherited dysregulation of the immune system, secondary HPS usually occurs in the context of infection or is linked to a neoplastic process. Clinical presentation varies and can potentially lead to life-threatening settings. While renal involvement has frequently been reported, however, detailed descriptions of the kidney manifestations of HPS are lacking. More critically, the diagnosis of HPS is rarely supported by renal biopsy specimens. We report four rare cases of biopsy-proven renal-limited HPS in patients presenting with acute kidney injury (AKI). The available evidence on this topic is critically discussed in light of the possible emergence of an autonomous entity characterized by an isolated kidney involvement.

Citing Articles

Concept and Diagnostic Challenges of Renal-Limited Hemophagocytic Syndrome/Macrophage Activation Syndrome.

Uchida T, Oda T J Clin Med. 2024; 13(8).

PMID: 38673434 PMC: 11050812. DOI: 10.3390/jcm13082161.


Glomerular lipidosis as a feature of renal-limited macrophage activation syndrome in a transplanted kidney: a case report.

Sugisaki K, Uchida T, Iwama S, Okihara M, Akashi I, Kihara Y BMC Nephrol. 2023; 24(1):329.

PMID: 37936128 PMC: 10631159. DOI: 10.1186/s12882-023-03380-2.


Autoinflammatory diseases and the kidney.

Hegazy M, Fayed A, Nuzzolese R, Sota J, Ragab G Immunol Res. 2023; 71(4):578-587.

PMID: 36991303 PMC: 10425501. DOI: 10.1007/s12026-023-09375-3.

References
1.
Parodi A, Davi S, Pringe A, Pistorio A, Ruperto N, Magni-Manzoni S . Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009; 60(11):3388-99. DOI: 10.1002/art.24883. View

2.
Minoia F, Bovis F, Davi S, Insalaco A, Lehmberg K, Shenoi S . Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr. 2017; 189:72-78.e3. DOI: 10.1016/j.jpeds.2017.06.005. View

3.
Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, Neven B, Picard C, Blanche S . Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007; 120(3):e622-8. DOI: 10.1542/peds.2006-3164. View

4.
Filippone E, Farber J . Hemophagocytic lymphohistiocytosis: an update for nephrologists. Int Urol Nephrol. 2016; 48(8):1291-1304. DOI: 10.1007/s11255-016-1294-z. View

5.
Barba T, Maucort-Boulch D, Iwaz J, Bohe J, Ninet J, Hot A . Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study. Medicine (Baltimore). 2015; 94(51):e2318. PMC: 4697985. DOI: 10.1097/MD.0000000000002318. View